US SEC Trading Suspension Halt Orders — September 28, 2026

Stock transfer to Nasdaq Capital Market effective September 24, 2026, extends compliance deadline to March 22, 2027, providing a 6-month window to regain $1.00 bid price, but signals persistent financial weakness and potential reverse split risk

Received Nasdaq Panel Notice on September 25, 2026, with a critical September 28, 2026 deadline to show $1.00 closing bid for 20 consecutive sessions, creating immediate binary event risk for shareholders

Chief Accounting Officer Michael J. Ragusa's resignation effective November 1, 2026, with CFO Lee A. Boyce assuming the role, indicates potential internal control or governance concerns during a critical compliance period

Company's ineligibility for additional compliance period under Rule 5810(c)(3)(A) due to failure to meet $5M initial listing equity requirement, limiting future flexibility and increasing delisting probability

Initial bid price deficiency disclosed March 24, 2026, with compliance period ending September 21, 2026, showing the company has already used its full initial period and now relies on the discretionary extension

Received prior delisting notices on July 24, 2026 (bid price) and August 17, 2026 (equity), indicating consecutive failures to meet multiple listing standards simultaneously

Potential reverse stock split is being considered as a compliance strategy, which could reduce share count but often leads to post-split selling pressure and further price declines

The Panel's additional condition of 20 consecutive sessions at $1.00 or greater is more stringent than typical requirements, reflecting heightened regulatory scrutiny of the company's financial viability

Must achieve $1.00 closing bid for 20 consecutive sessions by September 28, 2026, a deadline that has likely already passed or is imminent, creating extreme near-term delisting risk

Must meet $2.5M stockholders' equity requirement by January 4, 2027, but was previously ineligible for extension due to failing the $5M initial listing requirement, indicating severe capital inadequacy

CAO resignation effective November 1, 2026, during a compliance period, may signal internal disagreements or control weaknesses that could complicate the listing transfer process

Potential reverse stock split to regain compliance could be value-destructive, historically associated with 20-50% post-announcement declines in micro-cap stocks

Panel's stringent conditions and ineligibility for further extensions suggest Nasdaq views the company's continued listing as high-risk, potentially leading to suspension without additional warnings

The company has been non-compliant since at least March 2026, and the extended deadline of March 22, 2027, may not be sufficient if the stock price does not recover organically

The combination of bid price and equity deficiencies raises questions about the company's ability to continue as a going concern, potentially triggering auditor going-concern qualifications

The 180-day extension provides a defined timeline for potential strategic actions, including reverse split or operational improvements, which could create a short-term trading catalyst if the company announces a credible plan

CFO Lee A. Boyce's assumption of principal accounting officer role may bring fresh financial oversight, potentially improving reporting quality and investor confidence if executed smoothly

The Panel's decision to grant continued listing, despite prior deficiencies, suggests the company has presented a credible plan; successful compliance by September 28, 2026, could trigger a short squeeze or short-covering rally

The January 4, 2027 equity deadline creates a catalyst for potential capital raises or strategic investments, which could provide liquidity and support stock price if announced

If the company announces a reverse split with a clear timeline and support from major shareholders, the stock could see a temporary pop as investors position for compliance

The company's small market cap and overhang from delisting risk may create a mispricing opportunity for investors who believe the company can meet conditions, with potential for 2-3x upside if compliance is achieved

Both companies are small-cap names facing Nasdaq listing violations, indicating a broader trend of micro-cap companies struggling to maintain compliance amid volatile market conditions and higher regulatory standards

Both filings show companies relying on discretionary extensions and panel decisions, highlighting a pattern where Nasdaq provides multiple chances but with increasingly stringent conditions, reflecting a 'last chance' regulatory environment

Hain Celestial's CAO resignation during a compliance period suggests that governance and financial leadership instability often co-occur with listing challenges, creating compound risk for investors

The September 28, 2026 deadline for Nexalin and the September 24, 2026 transfer for Hain create a concentrated period of binary outcomes, emphasizing the need for investors to assess event risk in small-cap portfolios

Both companies' reliance on reverse splits and equity infusions indicates that micro-cap companies are facing significant capital structure stress, with dilution risk and going-concern concerns becoming more prevalent

Monitor whether the company achieves $1.00 closing bid for 20 consecutive sessions by September 28, 2026; any failure will likely result in immediate suspension or delisting

Watch for announcements regarding reverse split plans or operational improvements ahead of the March 22, 2027 deadline; any news of non-compliance could trigger sharp sell-offs

Monitor for potential capital raises or strategic investments to meet the $2.5M equity requirement by January 4, 2027; announcements could provide short-term trading opportunities

Watch for regulatory filings (e.g., 8-K) related to the CAO resignation effective November 1, 2026, and any potential internal control issues that may be disclosed

Monitor for any additional notices or conditions from the Panel, as the company may receive further requirements or warnings before the January 2027 deadline

Track daily closing prices for HAIN to assess the likelihood of regaining the $1.00 bid price; sustained weakness could force a reverse split announcement

Watch for any 10-K or 10-Q filings that may include going concern qualifications, which could further pressure the stock and trigger additional regulatory scrutiny